Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.65 USD | +11.84% | +12.95% | -12.12% |
05:09pm | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
05-07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.12% | 1.23B | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications